Celularity (CELU) Registration Filing summary

Company overview and business model

• Focuses on regenerative and cellular medicines targeting aging-related and degenerative diseases, leveraging off-the-shelf placental-derived allogeneic cell therapies and advanced biomaterials.

• Commercializes products like Biovance 3L and Rebound for wound care and soft tissue repair, and operates a biobanking service for stem cell storage.

• Pursues contract manufacturing and development services for third parties, aiming to assist development-stage cell therapy companies.

• Holds a robust global IP portfolio with over 350 patents and patent applications covering its platform and key programs.

Financial performance and metrics

• Reported $36.1M in revenue for the nine months ended September 30, 2024, a 239% YoY increase, driven by higher product sales and new distribution agreements.

• Net loss of $44.6M for the nine months ended September 30, 2024, with an accumulated deficit of $886.4M and cash and cash equivalents of $0.1M as of September 30, 2024.

• Cost of revenues for the nine months ended September 30, 2024 was $7.6M, with gross margin improvement due to higher-margin product mix.

• Significant reductions in R&D and SG&A expenses in 2023 and 2024 following workforce reductions and pipeline reprioritization.

• Substantial goodwill and IPR&D impairments in 2023 due to discontinued cell therapy programs.

Use of proceeds and capital allocation

• Expects net proceeds of approximately $13.3M from the offering, to be used for working capital and general corporate purposes.

• Management has broad discretion over use of proceeds, with no specific allocations detailed.